PE20210111A1 - Composiciones de proteina de fusion recombinante neuregulina-1 (nrg-1) humana y metodos para su uso - Google Patents

Composiciones de proteina de fusion recombinante neuregulina-1 (nrg-1) humana y metodos para su uso

Info

Publication number
PE20210111A1
PE20210111A1 PE2020001553A PE2020001553A PE20210111A1 PE 20210111 A1 PE20210111 A1 PE 20210111A1 PE 2020001553 A PE2020001553 A PE 2020001553A PE 2020001553 A PE2020001553 A PE 2020001553A PE 20210111 A1 PE20210111 A1 PE 20210111A1
Authority
PE
Peru
Prior art keywords
fusion protein
recombinant fusion
nrg
compositions
methods
Prior art date
Application number
PE2020001553A
Other languages
English (en)
Inventor
John Li
Shengwei Li
Dixiang Luo
Yiran Wu
Ming Zhou
Xiaolei Zhuang
Liang Hua
Pengyi Luo
Yang Wang
Original Assignee
Salubris Biotherapeutics Inc
Salubris Chengdu Biotech Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Salubris Biotherapeutics Inc, Salubris Chengdu Biotech Co Ltd filed Critical Salubris Biotherapeutics Inc
Publication of PE20210111A1 publication Critical patent/PE20210111A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/4756—Neuregulins, i.e. p185erbB2 ligands, glial growth factor, heregulin, ARIA, neu differentiation factor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • C07K16/1036—Retroviridae, e.g. leukemia viruses
    • C07K16/1045—Lentiviridae, e.g. HIV, FIV, SIV
    • C07K16/1063—Lentiviridae, e.g. HIV, FIV, SIV env, e.g. gp41, gp110/120, gp160, V3, PND, CD4 binding site
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/90—Stable introduction of foreign DNA into chromosome
    • C12N15/902—Stable introduction of foreign DNA into chromosome using homologous recombination
    • C12N15/907—Stable introduction of foreign DNA into chromosome using homologous recombination in mammalian cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/524—CH2 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/71—Decreased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Virology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cell Biology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • AIDS & HIV (AREA)

Abstract

La presente invencion hace referencia a una proteina de fusion recombinante que comprende un fragmento de neuregulina-1 (NRG-1) de proteina cardioprotectora fusionada a una estructura de anticuerpo monoclonal (mAb) y a un metodo para el tratamiento de una enfermedad o afeccion en un sujeto que lo necesita que comprende la administracion de una cantidad terapeuticamente eficaz de la proteina de fusion recombinante o la composicion farmaceutica que comprende la proteina de fusion recombinante descrita en la presente
PE2020001553A 2018-04-11 2019-04-11 Composiciones de proteina de fusion recombinante neuregulina-1 (nrg-1) humana y metodos para su uso PE20210111A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862656246P 2018-04-11 2018-04-11
PCT/US2019/026889 WO2019200033A1 (en) 2018-04-11 2019-04-11 Human neuregulin-1 (nrg-1) recombinant fusion protein compositions and methods of use thereof

Publications (1)

Publication Number Publication Date
PE20210111A1 true PE20210111A1 (es) 2021-01-19

Family

ID=66484143

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2020001553A PE20210111A1 (es) 2018-04-11 2019-04-11 Composiciones de proteina de fusion recombinante neuregulina-1 (nrg-1) humana y metodos para su uso

Country Status (21)

Country Link
US (3) US11046741B2 (es)
EP (2) EP4361177A2 (es)
JP (2) JP2021535727A (es)
KR (1) KR20210022542A (es)
CN (1) CN113166218A (es)
AU (2) AU2019252262B2 (es)
BR (1) BR112020020646A2 (es)
CA (1) CA3096420A1 (es)
CL (1) CL2020002621A1 (es)
CO (1) CO2020012621A2 (es)
DK (1) DK3774859T3 (es)
EA (1) EA202092458A1 (es)
FI (1) FI3774859T3 (es)
IL (1) IL277790A (es)
MX (1) MX2020010740A (es)
PE (1) PE20210111A1 (es)
PH (1) PH12020551648A1 (es)
PT (1) PT3774859T (es)
SG (1) SG11202009831UA (es)
TW (1) TWI834654B (es)
WO (1) WO2019200033A1 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11046741B2 (en) 2018-04-11 2021-06-29 Salubris Biotherapeutics, Inc. Human neuregulin-1 (NRG-1) recombinant fusion protein compositions and methods of use thereof
AR121035A1 (es) 2019-04-01 2022-04-13 Lilly Co Eli Compuestos de neuregulina-4 y métodos de uso
US20230057622A1 (en) * 2019-09-16 2023-02-23 Zensun (Shanghai) Science & Technology, Co., Ltd. Recombinant Human Neuregulin Derivatives and Use Thereof
WO2023178086A1 (en) * 2022-03-15 2023-09-21 Salubris Biotherapeutics, Inc. Methods of treating fibrosis and arrhythmia with a neuregulin-1 fusion protein

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5202238A (en) 1987-10-27 1993-04-13 Oncogen Production of chimeric antibodies by homologous recombination
US5204244A (en) 1987-10-27 1993-04-20 Oncogen Production of chimeric antibodies by homologous recombination
US5464764A (en) 1989-08-22 1995-11-07 University Of Utah Research Foundation Positive-negative selection methods and vectors
US5530109A (en) 1991-04-10 1996-06-25 Ludwig Institute For Cancer Research DNA encoding glial mitogenic factors
US5716930A (en) 1991-04-10 1998-02-10 Ludwig Institute For Cancer Research Glial growth factors
IL101943A0 (en) 1991-05-24 1992-12-30 Genentech Inc Structure,production and use of heregulin
US5834229A (en) 1991-05-24 1998-11-10 Genentech, Inc. Nucleic acids vectors and host cells encoding and expressing heregulin 2-α
US5541110A (en) 1994-05-17 1996-07-30 Bristol-Myers Squibb Cloning and expression of a gene encoding bryodin 1 from Bryonia dioica
US5912326A (en) 1995-09-08 1999-06-15 President And Fellows Of Harvard College Cerebellum-derived growth factors
AUPP785098A0 (en) * 1998-12-21 1999-01-21 Victor Chang Cardiac Research Institute, The Treatment of heart disease
US6635249B1 (en) 1999-04-23 2003-10-21 Cenes Pharmaceuticals, Inc. Methods for treating congestive heart failure
AU2002304965A1 (en) * 2002-05-24 2003-12-12 Zensun (Shanghai) Sci-Tech.Ltd Neuregulin based methods and compositions for treating viral myocarditis and dilated cardiomyopathy
WO2006017184A2 (en) * 2004-07-09 2006-02-16 Wayne State University HYBRID PROTEINS WITH ErbB4 EXTRACELLULAR DOMAIN AND NEUREGULIN HEPARIN-BINDING DOMAIN FOR TARGETING
US8142781B2 (en) * 2005-10-07 2012-03-27 Armagen Technologies, Inc. Fusion proteins for blood-brain barrier delivery
US20070213264A1 (en) * 2005-12-02 2007-09-13 Mingdong Zhou Neuregulin variants and methods of screening and using thereof
CN101827860A (zh) 2007-10-16 2010-09-08 西福根有限公司 包含最佳化her1和her3多聚体的组合物及其使用方法
US20090226435A1 (en) * 2008-03-08 2009-09-10 Sanjay Khare Engineered fusion molecules immunotherapy in cancer and inflammatory diseases
SG192496A1 (en) * 2008-07-08 2013-08-30 Abbott Lab Prostaglandin e2 binding proteins and uses thereof
JP5743898B2 (ja) 2008-11-28 2015-07-01 ゼンサン （シャンハイ） サイエンス アンド テクノロジー リミテッド ニューレグリンペプチド及びその使用
AU2010303443A1 (en) * 2009-10-09 2012-04-19 Merck Sharp & Dohme Corp. Generation, characterization and uses thereof of anti-Her 3 antibodies
CN102139095A (zh) 2010-01-29 2011-08-03 上海泽生科技开发有限公司 神经调节蛋白用于预防、治疗或延迟心脏缺血再灌注损伤的方法和组合物
US9029328B2 (en) * 2010-03-24 2015-05-12 The Brigham And Women's Hospital, Inc. Methods for cardioprotection and cardioregeneration with dimers of EGF family ligands
WO2013053076A1 (en) 2011-10-10 2013-04-18 Zensun （Shanghai）Science & Technology Limited Compositions and methods for treating heart failure
JP6449876B2 (ja) * 2013-11-07 2019-01-09 アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル ニューレグリンに対して非競合的でアロステリックな抗ヒトｈｅｒ３抗体及びその使用
CN110946993A (zh) 2014-01-03 2020-04-03 上海泽生科技开发股份有限公司 纽兰格林制剂的配方
PT3129063T (pt) * 2014-04-10 2021-04-01 Daiichi Sankyo Europe Gmbh Conjugado anticorpo anti-her3-fármaco
CA2959716A1 (en) * 2014-09-08 2016-03-17 Yeda Research And Development Co. Ltd. Anti-her3 antibodies and uses of same
CN105561298A (zh) 2014-10-17 2016-05-11 上海泽生科技开发有限公司 神经调节蛋白用于预防、治疗或延迟射血分数保留的心力衰竭的方法和组合物
IL260937B2 (en) 2016-02-06 2024-07-01 Epimab Biotherapeutics Inc FABS antibodies one by one and their uses
BR112019005001A2 (pt) 2016-09-15 2019-06-04 Univ Stuttgart proteína de ligação ao antígeno, proteína de fusão, ácido nucleico, vetor recombinante, célula hospedeira recombinante, composição farmacêutica, uso médico da proteína de ligação ao antígeno e método de inibição do crescimento tumoral
US11046741B2 (en) 2018-04-11 2021-06-29 Salubris Biotherapeutics, Inc. Human neuregulin-1 (NRG-1) recombinant fusion protein compositions and methods of use thereof

Also Published As

Publication number Publication date
AU2019252262A1 (en) 2020-10-22
US20230322877A1 (en) 2023-10-12
AU2023285793A1 (en) 2024-01-18
JP2021535727A (ja) 2021-12-23
FI3774859T3 (fi) 2024-05-24
TW201945389A (zh) 2019-12-01
US11046741B2 (en) 2021-06-29
IL277790A (en) 2020-11-30
CO2020012621A2 (es) 2020-12-21
CA3096420A1 (en) 2019-10-17
EP3774859A1 (en) 2021-02-17
US20200010522A1 (en) 2020-01-09
CL2020002621A1 (es) 2021-06-11
AU2019252262B2 (en) 2023-10-05
TWI834654B (zh) 2024-03-11
EA202092458A1 (ru) 2021-02-08
BR112020020646A2 (pt) 2021-02-23
DK3774859T3 (da) 2024-05-27
MX2020010740A (es) 2021-01-20
EP4361177A2 (en) 2024-05-01
CN113166218A (zh) 2021-07-23
SG11202009831UA (en) 2020-11-27
KR20210022542A (ko) 2021-03-03
US20210347841A1 (en) 2021-11-11
PT3774859T (pt) 2024-05-27
EP3774859B1 (en) 2024-03-13
WO2019200033A1 (en) 2019-10-17
JP2023134436A (ja) 2023-09-27
PH12020551648A1 (en) 2021-07-26
US11718652B2 (en) 2023-08-08

Similar Documents

Publication Publication Date Title
PE20210111A1 (es) Composiciones de proteina de fusion recombinante neuregulina-1 (nrg-1) humana y metodos para su uso
CL2020003096A1 (es) Anticuerpos frente a entpd2, terapias de combinación y métodos de uso de los anticuerpos y las terapias de combinación
PE20091449A1 (es) Proteinas de union a antigenos
PE20180120A1 (es) Proteinas de union a icos
CO2018005932A2 (es) Moléculas biespecíficas que tienen inmunorreactividad con pd-1 y ctla-4, y métodos de uso de las mismas
HRP20212028T1 (hr) Postupci za liječenje hiperlipidemije inhibitorom angptl8 i inhibitorom angptl3
PE20190976A1 (es) Anticuerpos de union a cd3
BR112019008010A2 (pt) anticorpo monoclonal isolado ou fragmento imunologicamente ativo do mesmo, anticorpo monoclonal biespecífico isolado, composição farmacêutica, método para tratamento de uma doença em um sujeito humano em necessidade do mesmo, proteína de fusão, epítopo imunodominante codificado pelo gene cd47, e, molécula biológica
CL2020001619A1 (es) Anticuerpos anti-cd33 y métodos para utilizarlos. (divisional solicitud 201903095)
BR112018072915A2 (pt) peptídeo cíclico isolado e composição farmacêutica
ECSP21010450A (es) Anticuerpos anti–sortilina y métodos para su uso
BR112022009273A2 (pt) Imunoglobulinas modificadas para direcionar depósitos amiloides
EA201892548A1 (ru) Антитела к альфа-синуклеину и их применение
GT200600182A (es) Anticuerpos dirigidos contra el peptido amiloide beta y metodo que utilizan los mismos
CL2008002668A1 (es) Anticuerpo que se une especificamente al polipeptido de linfopoyetina estromal timica (tslp); composicion farmaceutica que lo comprende; acido nucleico, vector de expresion, celula que lo comprende; hibridoma; metodo de produccion del anticuerpo; uso para tratar desorden inflamatorio relacionado a tslp o condicion fibrotica relacionada a tslp.
BRPI0821168B8 (pt) anticorpo isolado que se liga ao il-21 humano, ou um fragmento deste, usos de dito anticorpo ou fragmento, e, hibridoma
AR085198A1 (es) Composicion farmaceutica
PE20140882A1 (es) Anticuerpos neutralizantes de citomegalovirus humano
RU2013105769A (ru) Биологические материалы и их применение
HRP20231650T1 (hr) Cjepivo u kombinaciji sa inhibitorom imunološke kontrolne točke za primjenu u liječenju raka
MX2023013050A (es) Proteinas de fusion anticuerpo-peptido para el tratamiento de trastornos amiloides.
WO2017191327A3 (en) Her-2 binding antibodies
BR112021009912A2 (pt) Proteína de ligação a alfa receptor de folato, composição, e, método para produção da proteína de ligação a folr1
TW202426470A (zh) 人神經調節蛋白－１（ｎｒｇ－１）重組融合蛋白組成物及其使用方法
AR125589A1 (es) Métodos para el tratamiento de la enfermedad ocular tiroidea